Monopar Therapeutics — Form 8-K
Filed August 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On July 22, 2026, Monopar initiated a rolling NDA submission to the FDA for ALXN1840 (tiomolibdate choline) for Wilson disease treatment, with completion expected within months. The candidate received Rare Pediatric Disease designation on June 30, 2026, potentially qualifying for a Priority Review Voucher upon approval. Q2 2026 net loss was $5.3M ($0.62/share) vs. $2.5M ($0.35/share) in Q2 2025; cash position was $134.3M as of June 30, 2026, with runway through at least December 31, 2027.
Why this rating
Rolling NDA submission is a major regulatory milestone for a clinical-stage biotech; RPD/PRV pathway valuable. But meaningful clinical/approval risk remains; event is ~47% of market cap.
See more from August 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.